ESMO 2022

Dose-dense standard of care is the optimal care

DD is the champion!

My highlights of ESMO22

Dose-dense therapy is beneficial for all patients

Immuntherapy only for low risk patients?

QoL and longterm toxicity

Reduction of peripheral neuropathy with taxane therapy

Consolidating data from prospective studies

Long-term data on dose density therapy in chemotherapy

Roadmap for the adjuvant setting

Simple and cheap surgical technique may impact survival in early breast cancer

Endocrine response in eBC

Hand cooling and compression both effective in preventing chemotherapy-induced peripheral neuropathy

Dose dense is better

Rosta i tania technika chirurgiczna może wpływać na czas przeżycia we wczesnym raku piersi

Il vincitore e’ il dose dense!!

Schéma dose-dense bénéfique pour toutes les patientes

Datele trialurilor se consolideata

Chłodzenie rąk i terapia kompresyjna skutecznie obniżają ryzyko neuropatii obwodowej po leczeniu taksanami

I miei punti salienti di ESMO22

DATA: Still open questions on the optimal duration of extended adjuvant endocrine therapy? Greatest effect in the endocrine sensitive population. N+ higher risk. Contralateral disease with longer benefit

Unmeet needs and my wishes for 2022!

Who needs Chemo? Who does not? Is OFS plus endocrine Therapy sufficient without prior Chemo? Response Assessment before surgery

Tailoring Adjuvant Therapy

Status update - adjuvant IO. Are TILs prognostic?

How to deal with the negative SERD data?

Dose-dense CT Efficacy confirmed in the Nodal+ ER+ population. Do all luminal patients benefit? What about secondary malignancies?

ADC after ADC - is there any orientation?

Sacituzumab govitecan for everybody!

Negative and yet positive?!

Survival benefit in endocrine sensitive patients

Another option for heavily pre-treated HR+ advanced breast cancer patients

My highlights of ESMO22

Endocrine-based therapy may prove more effective than chemo in “triple-positive” advanced breast cancer

OS not significant, but re-assuring new data

New treatment option for heavily pre-treated patients with ER+ MBC

More therapy options for patients with HR+, HER2+ disease

New data re-inforces SG as a new option pre-treated HR+/HER2- patients

Discontinued development

HER2+ and still without chemotherapy

The third in the bunch

Survival benefit from SG in mBC

SG is a novel treatment option for HR+/HER2- disease

VEX has no place in chemotherapy of metastatic breast cancer

Exciting data, but Phase 3 studies are needed

CDK4/6i could be an option for selected ER+/HER2+ disease

TROPiCS-02 highlights

Update on biomarkers on ADCs of the DAISY trial

Interim analysis shows promising data on Abema in the 1st Line

TROPiCS-02 highlights

Nouvelle option thérapeutique pour les patientes lourdement prétraitées RH+ HER2-

Nuove opzioni di trattamento personalizzate per pazienti con tumore mammarioHR+/HER2+

Sopravvivenza globale nello studio MONARCH3

Sacituzumab Govitecan: Un farmaco per tutte?

I miei punti salienti di ESMO22

Nouvelles données des analyses expolratoires dans l’étude DAISY

Leczenie zaawansowanych raków „potrójnie dodatnich” oparte na hormonoterapii może okazać się bardziej skuteczne niż chemioterapia

SG come nuova opzione di cura Per pazienti con tumore mammario HR+/HER2-

Survie globale pas encore significative statistiquement mais données rassurantes

SG confirms benefit in OS, PFS, ORR, QoL, the new 2nd line Standard of Care? What will be the treatment sequence? A European, US and Asian Perspective

Interim OS Data & PFS Update for Abemaciclib hint towards final consistent OS benefit. We need to focus on resistance drivers.

SERDs: equal PFS benefit vs. endocrine therapy; adjuvant data to be expected

CDK4/6i plus Trastuzumab – a possible chemo-free option for triple positive patients?

Monarch-3: strong OS Survival; DAWNA-2: PFS in line with existing CDK4/6i; monarcHER: a chemo-free treatment option

ADC efficacy in perspective: SG overall survival benefit, efficacy comparable for HER2- and HER2low. ADC sequencing could become an option. We need data for earlier settings.

ADAURA Update - preventing relapse or just delaying it?

Is OS really needed?

Osimertinib stays standard adjuvant

Window for treatment selection

Pollution and lung cancer - one mechanism revealed

Liquid biopsy monitoring of EGFR-mutant lung cancer patients before and after surgery

Long term follow-up of ADAURA trial

INCREASE - to good to be true?

Osimertinib - curing or delaying relapse?

Neoadjuvant strategies for PD-L1 < 1 %

Double IO + chemoradiotherapy - is it feasible in borderline resectable stage III NSCLC patients?

Concurrent preoperative IO/CRT in early lung cancer

ADAURA revisited

ADAURA revisited

Osimertinib: una cura o ritarda la ripresa di malattia?

Langzeitdaten ADAURA

Liquid biopsie monitoring van patiënten met een EGFR mutatie voor en na chirurgie

Dubbele immunotherapie plus chemoradiotherapie - is het haalbaar bij patiënten met borderline resectable stadium III NSCLC?

Eine Plattform für "take the winner"-Strategie

Osimertinib bleibt Standard adjuvant

Pollution et cancer du poumon - un mécanisme mis en évidence

DFS matters!

Important data on borderline resectable patients

Sotorasib vs. Docetaxel in mKRAS G12C

Long term follow-up of KEYNOTE-189 and KEYNOTE-407

Can IO be discontinued?

One more brick in the KRAS G12C wall

Immunotherapy in unfit population? Perhaps...

New immunotherapy options for pts. ineligible to 1st line platinum therapy

If you don't look, vou don't find - once you found it, you'll treat it!

Is shorter immunotherapy equally effective and less physically demanding?

Induction chemoimmunotherapy in borderline resectability?

5-year data on survival under immunotherapy

New therapy combination after progression on 1L osimertinib

Preview on lung cancer highlights

Cemiplimab beyond progression?

Sotorasib: sweet and sour results

DESTINY-Lung02 - better than the original?

Atezolizumab better than vinorelbin in reduced performance status

HER2 - the next actionable mutation in lung cancer?

Can we finally treat poor prognostic patients with immunotherapy?

5 years of chemoimmunotherapy: solid grounded

Chemoimmunotherapy - improvement of survival after 5 years

Pneumonitis and T-DXd

Emerging IO mono options in the first line

Duration of immunotherapy : Stop and go strategy for Nivo/Ipi

Sotorasib - a new standard of care?

Question about timing and duration of immunotherapy still unanswered

Real-world data on Atezolizumab

A new step in treatment of KRAS G12C mutant NSCLC

5-year update on 1st line chemoimmunotherapy

The journey at KRAS G12C continues

Poseidon and STK11/KEAP

Liquid biopsy monitoring in treatment decisions

Cemiplimab beyond progression?

Una nueva opción de tratamiento con IO en pacientes no tributarios de 1L con platino

Un mattone in piu' nel muro del KRAS G12C

Pneumonitis und T-DXd

Kann IO pausiert werden?

Données de vie réelle avec l’atezolizumab

Kunnen we eindelijk patiënten met een slechte prognose behandelen met immunotherapie?

Atezo besser als Vino bei PS2-3

Sotorasib vs. Docetaxel bei mKRAS G12C

Chimio-immunothérapie - amélioration de la survie après 5 ans

Kürzere Immuntherapie gleich effektiv aber weniger belastend?

5-Jahresüberleben mit Immuntherapie

Liquid Biopsy Monitoring zur Therapiesteuerung

Neue Option der IO-Therapie in der Erstlinie

Durée de l'immunothérapie : stratégie Stop and Go pour l 'association Nivo/Ipi

Se non lo cerchi non lo troiv. Quando lo hai trovato, trattalo

Immunoterapia nella popolazione non fit: forse

Poseidon und STK11/KEAP

Resultados Agridulces de Sotorasib

Les études incontournables à l’ESMO 2022

IO-IO neoadjuvant bei PD-L1 neg.

Neue Therapiekombination in der Resistenz nach Osimertinib

Die Reise bei KRAS G12C geht weiter

Une nouvelle étape dans le traitement du CBNPC KRAS G12C muté

5 Jahre Chemo-Immuntherapie: starker Effekt

Chemo-IO-Induktion bei grenzwertiger Resektabilität?

A positive study! With a question mark?

New strategies in immunotherapy

Novel data and long-term efficacy of chemo-IO in mNSCLC

Heterogenity in the genetic landscape - little progress in molecular alterations

Exciting data for high-risk patients: is this the start of a new era?

Brief highlights about RCC & urothelial cancer from ESMO22

New combo - triplet therapy for kidney cancer

More questions being raised

Adjuvant Immuntherapy in kidney cancer

Place of triplet therapy

News in terms of adjuvant

Two negative studies question adjuvant approach in RCC

Adjuvant CPI in kidney cancer – 2 phase III trials with novel insights!

No value of IPI/Nivo in the adjuvant setting.

Immune-based peri-operative treatment in RCC: What went wrong?

Terapia triple para cancer renales

Inmunoterapia adyuvante en el cancer renales

Μηνύματα από το ESMO22 για τον καρκίνο του νεφρού

Tratamiento perioperatorio con immunoterapia en cáncer renal: Que ha fallado?

Shedding light on TKI/Checkpointinhibitor combinations

Immunomodulation in combination with checkpointinhibiton

Therapy combinations in RCC - what is the role of triplet therapy?

Adjuvant immunotherapy options in RCC - what do we learn from ESMO22 data for the adjuvant setting?

EV + Pembro with excellent response rates

Brief highlights about RCC & urothelial cancer from ESMO22

EV + pembrolizumab in cisplatin-ineligible patients

Μηνύματα από το ESMO22 για τον ουροθηλιακό καρκίνο

Adjuvant and neoadjuvant therapy approaches in urothelial cancer

Promising data, but beware of toxicity

Biomarker exploration in urothelial cancer - finding the right assay for the right drug!

QoL data from ARASENS triplet therapy study mHRPC

IM arbiraterone decanoate might demonstrate superior therapeutic index and tolerability

Should intensification of ADT be considered in high-risk biochemically relapsed PC?

IO + PARP without benefit in the allcomer situation

ADT + ENZA better choice than monotherapy

Update on the PROpel study

Cabazitaxel better tolerated in elderly men

Combination of olaparib leads to promising results

Triplet therapy with darolutamide in prostate cancer

In older vulnerable - less is more

PSA at 8-months as a biomarker

Biomarker data for better patients selection

ADCs - a possible therapeutic approach

Optimizing cabazitaxel chemotherapy

Radicals - ADT & Radiotherapy

Further evaluation of PSA correlates

Length of hormone therapy after radiation

Genetic testing before PARP therapy is useful

Livskvalitetsuppföljning i ARASENS studien

Uppdatering i PROpel studien

PSA efter 8 månader i PEACE-1 studien som biomarkör

Intimate partner violence in cancer patients

TILs - Fashion is the eternal return of the old

Novel approach von Biontech towards Cancer – game changing potential?!

Addition of CPI to Radiochemotherapy in LA-HNSCC?

IAP-inhibition – comming game changer in LA-HNSCC Radiochemotherapy

New group of substances for rare diseases